Format

Send to

Choose Destination
Biotechnol Adv. 2011 Jul-Aug;29(4):436-41. doi: 10.1016/j.biotechadv.2011.03.005. Epub 2011 Apr 2.

Longer action means better drug: tuning up protein therapeutics.

Author information

1
Faculty of Biotechnology, University of Wroclaw, Tamka 2, 50-137 Wroclaw, Poland.

Abstract

An increasing number of proteins are currently available on the market as therapeutics and this branch of the pharmaceutical industry will expand substantially during the coming years. As many diseases result from dysfunction of proteins forming multicomponent complexes, protein drugs with their inherent high specificity and affinity seem to be optimal medical agents. On the other hand, proteins are often highly instable and sensitive to degradation, which questions their applicability as effective therapeutics. Therefore, redesign and engineering of proteins is usually a required step in the present day drug development. Several approaches have been applied to optimize the protein properties central to their pharmaceutical use. This review focuses on different strategies that improve two crucial factors influencing protein drug efficiency: protein stability and its in vivo half-life. We provide examples of successful genetic and chemical modifications applied in the design of effective protein therapeutics.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center